Does Rallies show Form 4 insider transactions for ACTU?

Yes. Rallies tracks ACTU insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACTU research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACTU. It does not provide personalized investment advice.

ACTU (Actuate Therapeutics, Inc. Common stock) Stock Analysis - Insider Trades

Actuate Therapeutics, Inc. Common stock (ACTU) is a publicly traded Healthcare sector company. As of May 21, 2026, ACTU trades at $2.51 with a market cap of $58.14M and a P/E ratio of -2.36. ACTU moved +3.33% today. Year to date, ACTU is -60.41%; over the trailing twelve months it is -76.32%. Its 52-week range spans $1.58 to $11.99. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces ACTU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACTU stock inside the company?

Recent ACTU insider activity includes THOMSON TODD S sold 280.00K, Bios Equity COF, LP bought 71.43K, Kreis Leslie W. bought 71.43K, Fletcher Aaron G.L. bought 71.43K, and Bios Equity COF, LP sold 5.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACTU Key Metrics

Key financial metrics for ACTU
Metric	Value
Price	$2.51
Market Cap	$58.14M
P/E Ratio	-2.36
EPS	$-1.06
Dividend Yield	0.00%
52-Week High	$11.99
52-Week Low	$1.58
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-22.23M
Gross Margin	0.00%

Recent ACTU Insider Trades

THOMSON TODD S sold 280.00K (~$1.62M) on Jan 5, 2026.
Bios Equity COF, LP bought 71.43K (~$500.00K) on Jun 27, 2025.
Kreis Leslie W. bought 71.43K (~$500.00K) on Jun 27, 2025.
Fletcher Aaron G.L. bought 71.43K (~$500.00K) on Jun 27, 2025.
Bios Equity COF, LP sold 5.31K (~$42.51K) on Aug 14, 2024.

Latest ACTU News

Actuate Therapeutics Targets $200M+ Pediatric Voucher with Oral Elraglusib and RAS Trials — Mar 24, 2026
Actuate Therapeutics Shares Down 49.2%; Q4 Results Slated for March 12 — Feb 6, 2026

ACTU Analyst Consensus

2 analysts cover ACTU: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.

Common questions about ACTU

Who is trading ACTU stock inside the company?: Recent ACTU insider activity includes THOMSON TODD S sold 280.00K, Bios Equity COF, LP bought 71.43K, Kreis Leslie W. bought 71.43K, Fletcher Aaron G.L. bought 71.43K, and Bios Equity COF, LP sold 5.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACTU?: Yes. Rallies tracks ACTU insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACTU research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACTU. It does not provide personalized investment advice.